Image credit: Canva
Throat cancer is a type of tumor that can occur in people infected with the human papillomavirus (HPV). Researchers believe that adding an immunotherapy vaccine (PRGN-2009) to chemotherapy drugs may improve survival without the need for radiation. A clinical trial led by Clint T. Allen, M.D., Senior Investigator in the Surgical Oncology Program, is researching combination immunotherapy for HPV-associated throat cancer.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the NIH Clinical Center.
For more information, please contact Erica Redmond at erica.redmond@nih.gov
Clinicaltrials.gov identifier: NCT06223568
NCI Protocol ID: IRB001730
Official Title: Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
